HIV control: Is getting there the same as staying there?

P Goulder, SG Deeks - PLoS pathogens, 2018 - journals.plos.org
P Goulder, SG Deeks
PLoS pathogens, 2018journals.plos.org
In this brief review and perspective, we address the question of whether the immune
responses that bring about immune control of acute HIV infection are the same as, or distinct
from, those that maintain long-term viral suppression once control of viremia has been
achieved. To this end, we describe the natural history of elite and post-treatment control,
noting the lack of data regarding what happens acutely. We review the evidence suggesting
that the two clinical phenotypes may differ in terms of the mechanisms required to achieve …
In this brief review and perspective, we address the question of whether the immune responses that bring about immune control of acute HIV infection are the same as, or distinct from, those that maintain long-term viral suppression once control of viremia has been achieved. To this end, we describe the natural history of elite and post-treatment control, noting the lack of data regarding what happens acutely. We review the evidence suggesting that the two clinical phenotypes may differ in terms of the mechanisms required to achieve and maintain control, as well as the level of inflammation that persists once a steady state is achieved. We then describe the evidence from longitudinal studies of controllers who fail and studies of biologic sex (male versus female), age (children versus adults), and simian immunodeficiency virus (SIV) (pathogenic/experimental versus nonpathogenic/natural infection). Collectively, these studies demonstrate that the battle between the inflammatory and anti-inflammatory pathways during acute infection has long-term consequences, both for the degree to which control is maintained and the health of the individual. Potent and stringent control of HIV may be required acutely, but once control is established, the chronic inflammatory response can be detrimental. Interventional approaches designed to bring about HIV cure and/or remission should be nuanced accordingly.
PLOS